ИИ ежедневно анализирует ведущие российские и международные источники, отбирает значимые исследования, рекомендации и новости и представляет их врачу в кратком структурированном формате.
Конференции, вебинары и симпозиумы по онкологии от ведущих организаций мира.
Организатор: ESMO Meeting Calendar
Организатор: ESMO Meeting Calendar
Организатор: Decera Clinical
In this podcast, experts discuss the evolving role of TROP2-directed antibody–drug conjugates (ADCs) in NSCLC, highlighting current clinical applications, emerging efficacy and safety data, and future treatment strategies. The discussion reviews evidence supporting the use of datopotamab deruxtecan (Dato-DXd) in previously treated EGFR-mutated NSCLC and considerations for treatment selection and sequencing. Emerging data for investigational TROP2 ADCs, including sacituzumab tirumotecan, and findings from ongoing trials evaluating ADC combinations with immunotherapy, chemotherapy, and EGFR-targeted therapies are explored. The experts also address the potential role of the TROP2 QCS-NMR biomarker in identifying patients most likely to benefit from treatment, challenges in interpreting clinical trial outcomes, and practical strategies for preventing and managing adverse events, including stomatitis, ocular toxicity, and interstitial lung disease/pneumonitis. These considerations provide context for integrating TROP2 ADCs into clinical practice as evidence continues to evolve.
Организатор: Decera Clinical
Explore current melanoma immunotherapy strategies for resectable and metastatic disease, including neoadjuvant and adjuvant treatment, pathologic response assessment, individualized neoantigen therapy, and treatment sequencing. Review recent clinical trial evidence, immune-related adverse event management, and multidisciplinary workflows to support personalized care.
Организатор: Decera Clinical
In this on-demand webcast, an expert reviews the pathophysiology, risk assessment, prevention, and management of tumor lysis syndrome (TLS), a potentially life-threatening oncologic emergency associated with hematologic malignancies and certain anticancer therapies. The faculty examines disease-, patient-, and treatment-related risk factors for TLS, including tumor burden, renal function, and the use of novel agents such as venetoclax, bispecific antibodies, and CAR T-cell therapies. Clinical evidence and practical considerations for TLS prevention and management are highlighted, including risk stratification, laboratory monitoring, hydration, correction of electrolyte abnormalities, and uric acid–lowering therapies such as allopurinol, febuxostat, and rasburicase. Particular attention is given to TLS risk mitigation during venetoclax initiation in CLL and AML, including dose ramp-up strategies, laboratory monitoring schedules, and criteria for inpatient versus outpatient treatment. Case-based discussions and institutional protocol considerations emphasize individualized prophylaxis, early recognition of metabolic disturbances, multidisciplinary coordination, and standardized approaches to TLS management to reduce complications and support the safe administration of anticancer therapies.
Организатор: Decera Clinical
Организатор: ESTRO
Организатор: НМИЦ онкологии им. Н.Н. Петрова
Организатор: Decera Clinical
Организатор: Decera Clinical
These downloadable slides on the neurosurgical management of H3 K27-altered diffuse midline glioma (DMG) focus on the role of stereotactic biopsy, molecular diagnosis, and treatment planning. Topics include evaluating the risks and benefits of tissue acquisition based on tumor location and clinical presentation; optimizing biopsy techniques and tissue stewardship to support integrated molecular diagnosis; and interpreting H3 K27M immunohistochemistry, H3K27me3 assessment, sequencing, and cerebrospinal fluid tumor DNA testing. The slides also review clinical evidence supporting dordaviprone in progressive H3 K27–mutant DMG, the ongoing phase III ACTION trial, and investigational approaches including ONC206 and CAR T-cell therapies targeting GD2 and B7-H3. Additional considerations include managing neurologic deterioration and hydrocephalus, coordinating multidisciplinary care, and optimizing referral timing and procedural planning to preserve treatment and clinical trial opportunities.
Организатор: Decera Clinical
These downloadable slides focus on the recognition and management of adverse events associated with CAR T-cell therapies and bispecific antibodies in patients with hematologic malignancies, with a focus on emergency department care. The slides review the clinical manifestations, timing, and grading of CRS and ICANS, including differentiation from infection, stroke, and other acute conditions. Evidence-based approaches to initial assessment, stabilization, treatment, and escalation of care are highlighted, along with product-specific monitoring requirements and delayed toxicities. Practical strategies for identifying treatment exposure, navigating evolving REMS requirements, and coordinating care across emergency medicine, oncology, and pharmacy teams are also addressed to support timely intervention and appropriate clinical decision-making.
Организатор: Decera Clinical
In this commentary, experts answer nuanced audience questions from a recent workshop series on relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), discussing how prior therapy, mechanisms of resistance, comorbidities, disease characteristics, and patient preferences inform treatment sequencing. Faculty highlight recent developments in moving the noncovalent BTK inhibitor pirtobrutinib into earlier lines of therapy, including the BRUIN CLL-313 and BRUIN CLL-322 studies, and discuss patient education and resources, venetoclax retreatment strategies, resistance mutation testing, and how to sequence pirtobrutinib and CAR T-cell therapy.
Организатор: Decera Clinical
The expanding range of JAK inhibitor options in myelofibrosis has increased the need for individualized treatment decisions that account for disease characteristics, molecular findings, prior therapy, comorbidities, cytopenias, symptoms, and patient-specific goals. This Interactive Decision Support Tool applies key patient and disease characteristics to treatment selections and compares their intended approach with recommendations from MF experts, exploring how clinical evidence, supportive care needs, and patient factors can inform personalized, equitable management across diverse patient populations.
Организатор: Decera Clinical
In this on-demand webcast, an expert reviews the role of HER2 testing and HER2-directed therapies in gynecologic cancers, with a focus on endometrial, ovarian, and cervical cancers. They examine HER2 protein expression, gene amplification, and activating mutations; tumor-specific testing and scoring criteria; and factors contributing to discordant results, including tumor heterogeneity, specimen selection, and assay variability. Clinical evidence supporting HER2-directed treatment strategies is highlighted, including efficacy and safety findings from the DESTINY-PanTumor02 and STATICE trials evaluating trastuzumab deruxtecan, along with emerging data on investigational HER2-directed ADCs and ongoing clinical trials. Case-based discussions address the interpretation of HER2 results, treatment selection based on tumor histology and biomarker status, and strategies for monitoring and managing treatment-related adverse events, particularly ILD/pneumonitis.
Организатор: Decera Clinical
In this commentary, advanced practice providers who are experts in breast cancer discuss the evolving role of oral estrogen receptor–directed therapies in HR-positive/HER2-negative metastatic breast cancer, with a focus on overcoming endocrine resistance and individualizing treatment. The discussion examines the clinical significance of ESR1 mutations, optimal timing and interpretation of ctDNA testing, and phase III efficacy data from EMERALD, EMBER-3, VERITAC-2, and SERENA-6. Particular attention is given to biomarker-guided treatment selection, including the potential for early therapeutic intervention following detection of emerging ESR1 mutations before clinical disease progression, and sequencing strategies when multiple actionable alterations are present. The experts also address agent-specific safety considerations, adverse event monitoring and management, patient counseling, adherence, and practical barriers to care, emphasizing the importance of balancing treatment efficacy, tolerability, and quality of life.
Организатор: Decera Clinical
Организатор: SNMMI Upcoming Events
Организатор: ESMO Meeting Calendar
Организатор: ESMO Meeting Calendar
These downloadable slides provide evidence on antibody–drug conjugates in endometrial cancer and present information about the molecular classification of endometrial cancer, algorithms for first-line and second-line therapy and data from clinical trials like GOG-3031/RUBY, NRG-GY018/KEYNOTE-868, and DUO-E/GOG-3041/ENGOT-EN10. In addition, the toxicities associated with antibody–drug conjugates are outlined. Major disparities in endometrial cancer with incidence, outcomes, and biomarkers are also highlighted.
Организатор: Decera Clinical
The treatment landscape of R/R mantle cell lymphoma continues to evolve as the use of covalent BTK inhibitors further expands into the first-line setting. These slides contain the latest data, guidelines, and expert recommendations for managing R/R disease post covalent BTK inhibitor. Highlights include the similarities and differences between small molecules pirtobrutinib and sonrotoclax including patient selection, step-up dosing requirements, TLS monitoring, efficacy post covalent BTKi, and implementing treatment in community practices. They also include the efficacy, safety, and best practices of CAR T-cell therapy and bispecific antibodies.
Организатор: Decera Clinical
Организатор: ESMO Meeting Calendar
Организатор: SITC Events
Ежегодная площадка онкопсихологов: доказательная онкопсихология, сопровождение пациентов и семей, детская онкопсихология, паллиативная помощь, профилактика выгорания. Только очно.
Организатор: Национальная ассоциация онкопсихологов и служба «Ясное утро»
Организатор: European Society of Pathology — Events
Организатор: European Society of Pathology — Events
Enhance your ability to apply current and emerging evidence on BCMA- and GPRC5D-directed bispecific antibody strategies to improve your care for patients with relapsed/refractory multiple myeloma through this certified on-demand webcast. Topics covered include differentiation of BCMA- and GPRC5D-directed agents, step-up dosing and REMS workflows, infection prevention, CRS/ICANS triage, GPRC5D-specific supportive care, patient/caregiver counseling, and more.
Организатор: Decera Clinical
Организатор: OncoSib — Ассоциация онкологических организаций Сибири и ДВ
Организатор: IASLC Conferences
Организатор: Onco-Academy
In this on-demand webcast, experts discuss how advances in biomarker testing and targeted therapy are reshaping the management of ROS1-rearranged non-small-cell lung cancer (NSCLC). Through a practical review of the latest clinical evidence, experts explore strategies for identifying ROS1 fusions, selecting and sequencing available and emerging ROS1-targeted therapies, and balancing efficacy, intracranial activity, and treatment-related toxicities when individualizing care. The discussion also examines approaches to disease progression and acquired resistance, including the ROS1 G2032R mutation and other on- and off-target resistance mechanisms. Learners will gain insights into how molecular testing, CNS involvement, resistance profiles, and patient-specific considerations can be integrated into treatment decisions across the continuum of care for patients with ROS1-rearranged NSCLC.
Организатор: Decera Clinical
New approvals in the neoadjuvant and adjuvant settings of HER2-positive early breast cancer are increasing the complexity of selecting optimal treatment. This patient case challenges you to navigate treatment selection based on specific patient clinical presentation characteristics, including response to neoadjuvant treatment, best practices for sequencing adjuvant radiation therapy, and management through treatment-related adverse events based on the currently available evidence.
Организатор: Decera Clinical
As TROP2-directed antibody–drug conjugates (ADCs) reshape the treatment landscape for advanced non-small-cell lung cancer (NSCLC), healthcare professionals face important questions about treatment sequencing, patient selection, and toxicity management. In this commentary, experts examine emerging clinical evidence for datopotamab deruxtecan and sacituzumab tirumotecan, the potential role of predictive biomarkers, and opportunities to integrate ADCs into earlier treatment settings. They also discuss practical strategies for managing adverse events and highlight the importance of balancing efficacy, tolerability, and quality of life to optimize individualized patient care.
Организатор: Decera Clinical
Организатор: MASCC Supportive Care Events
Организатор: MASCC Supportive Care Events
Организатор: НМИЦ онкологии им. Н.Н. Петрова
Организатор: College of American Pathologists (CAP) Events
Организатор: Decera Clinical
Организатор: Decera Clinical
Организатор: Decera Clinical
Организатор: International Psycho-Oncology Society (IPOS)
Организатор: ESTRO
Организатор: International Psycho-Oncology Society (IPOS)
Организатор: Onco-Academy
Организатор: International Psycho-Oncology Society (IPOS)
Организатор: Decera Clinical
Watch this on-demand webcast to discover the latest evidence and best practices for optimizing oral next-generation estrogen receptor (ER)–directed therapies in ER-positive/HER2-negative metastatic breast cancer through key clinical trial data presented alongside guidance on treatment selection, adverse event recognition and management, patient counseling, adherence, and more. Viewers will learn how to translate biomarker and efficacy data into individualized treatment decisions while helping patients navigate the practical and safety considerations of oral endocrine therapy.
Организатор: Decera Clinical
In this on-demand webcast, an expert reviews the evolving role of immune checkpoint inhibitors (ICIs) in the management of basal cell carcinoma and cutaneous squamous cell carcinoma, with a focus on treatment selection, emerging clinical evidence, and toxicity management. Clinical trial and real-world data on approved PD-1 and PD-L1 inhibitors, including cemiplimab, pembrolizumab, and cosibelimab, are examined, along with evidence supporting neoadjuvant and adjuvant immunotherapy in patients with high-risk or advanced disease. Findings from key studies, including EMPOWER-CSCC-1, KEYNOTE-629, C-POST, KEYNOTE-630, and MATISSE, highlight treatment efficacy, pathologic responses, recurrence outcomes, and considerations for integrating immunotherapy with surgery and radiation. The expert also discusses recognition and management of immune-related adverse events, particularly cutaneous and endocrine toxicities, and emerging approaches such as intralesional immunotherapy, combination regimens, and response-adapted treatment strategies. Case-based discussions emphasize the importance of multidisciplinary collaboration, individualized risk assessment, and shared decision-making when incorporating ICIs into clinical practice.
Организатор: Decera Clinical
Организатор: MASCC Supportive Care Events
Организатор: Association for Molecular Pathology — Events
Организатор: EAU
Get practical guidance on a wide range of hematologic malignancies at this exciting satellite symposia held both in-person in New Orleans and virtually.
Организатор: Decera Clinical
Get access to presentation slidesets, on-demand webcasts, and expert commentaries on oncology & hematology topics.
Организатор: Decera Clinical
With Decera Clinical Education (formerly CCO) access the latest oncology CME/CE activities and live events on breast, lung, hematologic, and other cancer types. Get evidence-based education for the entire oncology care team.
Организатор: Decera Clinical
Организатор: Decera Clinical
Организатор: Decera Clinical
Организатор: Decera Clinical
Организатор: Decera Clinical
Организатор: Decera Clinical
Организатор: Decera Clinical
In this commentary, experts discuss the evolving treatment landscape of R/R mantle cell lymphoma as the use of covalent BTK inhibitors further expands into the first-line setting. The discussion highlights the similarities and differences between the approved small molecule inhibitors pirtobrutinib and sonrotoclax, including patient selection, step-up dosing requirements, TLS monitoring, efficacy post covalent BTKi, sequencing, and the feasibility of implementing treatment in community practices. They also examine the efficacy and safety of CAR T-cell therapy and bispecific antibodies, describing their current and possible future roles in R/R mantle cell lymphoma.
Организатор: Decera Clinical
In this commentary, an expert discusses individualized treatment selection and sequencing in myelofibrosis, emphasizing the integration of prognostic risk, clinical phenotype, and patient-specific factors. The commentary examines the role of anemia, thrombocytopenia, splenomegaly, and symptom burden in guiding JAK inhibitor selection, including considerations for ruxolitinib, fedratinib, pacritinib, and momelotinib. Drawing on clinical trial evidence, prescribing information, and expert experience, the discussion addresses assessment of treatment response, recognition of JAK inhibitor resistance or intolerance, and strategies for managing evolving clinical needs. The expert also highlights the importance of early transplant evaluation, clinical trial participation, and patient-centered decision-making to inform treatment sequencing and optimize care throughout the disease course.
Организатор: Decera Clinical
The care of patients with high-risk smoldering multiple myeloma (MM) or newly diagnosed MM requires an individualized, risk-adapted approach at every stage. This commentary covers evidence for subcutaneous daratumumab monotherapy from the AQUILA trial for high-risk MM, and the utility of quadruplets for patients with newly diagnosed MM based on the results from the PERSEUS, CASSIOPEIA, GMMG-HD7, and CEPHEUS trials, as well as support for intensified maintenance based on the AURIGA trial results.
Организатор: Decera Clinical
Experts answer questions related to the program, “CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies.” This social media forum provides learners with ongoing access to faculty throughout the certified life of this program.
Организатор: Decera Clinical
CDH6-directed therapy is rapidly evolving from a translational concept toward potential clinical relevance as emerging data from clinical trials of CDH6-targeted antibody–drug conjugates become available. To integrate new advances, healthcare professionals must be prepared to interpret the data, understand biomarker strategies, and anticipate how new agents may be included in existing treatment paradigms. This short commentary will equip them with the clinical insight, decision-making skills, and confidence needed to improve outcomes for patients with ovarian cancer by learning about the advances of CDH6-targeted agents.
Организатор: Decera Clinical
Use this Interactive Decision Support Tool to compare your choices of therapy for patients with relapsed/refractory multiple myeloma with those of 5 renowned experts.
Организатор: Decera Clinical
This podcast explores the evolving treatment landscape for marginal zone lymphoma (MZL), focusing on individualized treatment selection, emerging cellular therapies, and novel T-cell–engaging approaches for relapsed/refractory disease. Examine evidence supporting current treatment options, including BTK inhibitors and CAR T-cell therapy, as well as emerging clinical data on CD20 x CD3 bispecific antibodies such as odronextamab and mosunetuzumab. The discussion also addresses clinical trial referral, patient eligibility, and practical strategies for monitoring and managing treatment-related toxicities, including cytokine release syndrome, infections, and hypogammaglobulinemia.
Организатор: Decera Clinical
Организатор: Society for Neuro-Oncology — Events Calendar
Организатор: Society for Neuro-Oncology — Events Calendar
Научный клуб онкологии, радиотерапии и реконструктивной хирургии им. Л.Л. Левшина и СНК ортодонтии и профилактики приглашают на совместное заседание «Меланома слизистой полости рта: от первых признаков до тактики лечения». В рамках мероприятия организаторы объединят онкологию и стоматологию, чтобы обсудить редкую, но крайне важную патологию — меланому слизистой оболочки полости рта. Как отличить хроническую травму слизистой от потенциально злокачественного процесса? Какие изменения требуют особой онкологической настороженности? И какую тактику выбрать при выявлении меланомы? В программе заседания: 1. «Онконастороженность при хронической травме слизистой полости рта (декубитальные язвы и эрозии)» — Феттер Александра. 2. «Хроническая травма слизистой полости рта и гальванизм: лейкоплакия и риск предраковых изменений» — Сибулаева Самира. 3. Разбор клинических случаев — Михайлиди Филипп Дмитриевич, студент 4 курса Института клинической медицины Сеченовского Университета; Баканева Евгения Игоревна, ординатор 1-го года НМИЦ онкологии им. Н.Н. Блохина. 4. «Меланома слизистой оболочки полости рта: диагностика и тактика лечения» — Киселева Алевтина Эдуардовна, кандидат медицинских наук, врач-онколог, хирург. На заседании разберём реальные клинические ситуации, обсудим диагностические ошибки, маршрутизацию пациентов и современные подходы к лечению. Кого ждём: студентов медицинских и стоматологических факультетов, ординаторов и всех, кто интересуется онкологией, стоматологией и междисциплинарной медициной. 12 ноября 2026 года (четверг), начало в 16:00. Москва, ул. Можайский Вал, д. 11, Институт стоматологии, конференц-зал. Регистрация обязательна.
12–13 ноября 2026 года в Москве состоится IV ежегодная научно-практическая конференция «Академия CAR-T. День +3 CAR-T-клеточной терапии». Участники представят последние результаты применения клеточной терапии в России и обозначат перспективные векторы исследований и разработок. В конференции примут участие ведущие эксперты, специализирующиеся на клеточных технологиях. Ещё недавно CAR-T-клеточная терапия казалась научной фантастикой: собственные клетки пациента в лаборатории перепрограммируют так, чтобы они «находили» и «уничтожали» раковые клетки. Сегодня это стало реальностью. За пять лет объём клинических исследований в этой области вырос на 500%. Знаковым событием 2026 года стало включение анти-CD19 CAR-T-клеточной терапии в перечень видов высокотехнологичной медицинской помощи (ВМП-IV) в рамках программы государственных гарантий. Для успешного применения CAR-T-терапии и минимизации рисков для пациента необходима координация усилий биологов, специалистов по производству и медицинских работников. Поэтому в программе конференции значительное внимание будет уделено взаимодействию биологов и врачей в клинической практике, а также методам лечения осложнений и критических состояний, возникающих в процессе CAR-T-терапии. В рамках двухдневной программы участники обсудят весь цикл — от ранней и доклинической разработки клеточного продукта, лицензирования производства и системы контроля качества до применения и отслеживания результатов лечения. Отдельное внимание — месту клеточной терапии во взрослой и педиатрической практике, результатам применения CAR-T в России у пациентов с В-клеточными опухолевыми заболеваниями системы крови, особенностям проведения и мониторинга CAR-T-клеточной терапии. Состоится круглый стол, где представители регулятора, фармацевтической отрасли и государственных медицинских центров обсудят трудности запуска производства клеточных продуктов на площадке отечественного академического центра. Конференция станет площадкой для междисциплинарного диалога между врачами, биологами, специалистами по клинической лабораторной диагностике, сотрудниками производства и контроля качества, а также представителями фармацевтической отрасли. Организаторы: ФГБУ «НМИЦ гематологии» Минздрава России, Национальное гематологическое общество, Благотворительный фонд «Фонд борьбы с лейкемией», Центр высокоточных генетических технологий для медицины. При поддержке ООО «АстраЗенека Фармасьютикалз» и АО «Р-Фарм». Участие — по предварительной регистрации на сайте конференции.
Организатор: SNO/ASCO CNS Metastases Conference
Организатор: SITC Events
Организатор: IASLC Conferences
Организатор: SNO/ASCO CNS Metastases Conference
Организатор: Society for Neuro-Oncology Annual Meeting
Организатор: OncoSib — Ассоциация онкологических организаций Сибири и ДВ
Организатор: Society for Neuro-Oncology Annual Meeting
Организатор: College of American Pathologists (CAP) Events
12 ноября 2026 года состоится VII Онкологический онлайн-марафон «Онлайн-осень». Ежегодная осенняя встреча профессионального сообщества посвящена обсуждению ключевых изменений в онкопрактике за текущий период и определению приоритетных направлений работы онкослужбы. Программа объединяет клинические и организационные вопросы онкологии, охватывая широкий спектр направлений: от современных подходов к диагностике и лечению злокачественных новообразований до актуальных задач организации специализированной медицинской помощи. Среди ключевых тематик научной повестки мероприятия: организация онкологической помощи, диагностика и лечение опухолей лёгких, органов головы и шеи, молочной железы, системы крови, пищеварительного тракта, женской и мужской мочеполовой системы, редких опухолей (нейроонкология, меланома, опухоли костей и мягких тканей), а также другие важные вопросы онкологии. Марафон ориентирован на практикующих врачей-онкологов и специалистов смежных направлений, главных врачей медицинских организаций, руководителей онкологических служб и профильных подразделений, а также организаторов здравоохранения. Документация мероприятия подана на аккредитацию баллами НМО. Участие бесплатное.
Организатор: Society for Neuro-Oncology — Events Calendar
Организатор: ASTCT Meetings
Организатор: European Society of Pathology — Events
Организатор: НМИЦ онкологии им. Н.Н. Петрова
Организатор: ESMO Meeting Calendar
Организатор: OncoSib — Ассоциация онкологических организаций Сибири и ДВ
13 ноября 2026 г. в г. Уфа состоится Школа «Современные подходы к лечению онкоурологических заболеваний». Школа является комплексным мероприятием, всесторонне освещающим вопросы оказания помощи пациентам с онкоурологической патологией: скрининга, диагностики, лечения локализованных и распространенных форм урологических ЗНО. Формат: очно.
Организатор: Российское общество онкоурологов
Организатор: НМИЦ радиологии Минздрава России
Организатор: College of American Pathologists (CAP) Events
Организатор: ESTRO
Организатор: ESMO Meeting Calendar
Организатор: College of American Pathologists (CAP) Events
Организатор: SIOP Community Calendar
Организатор: ESMO Meeting Calendar
Организатор: College of American Pathologists (CAP) Events
Организатор: EAU
Организатор: College of American Pathologists (CAP) Events
Организатор: ASTCT Meetings
Организатор: НМИЦ онкологии им. Н.Н. Петрова
Организатор: MASCC Supportive Care Events
Организатор: SITC Events
Организатор: ESMO Meeting Calendar
Организатор: ESMO Meeting Calendar
Организатор: Onco-Academy
Организатор: EBMT Educational Events & Meetings
Ежегодная встреча Общества нейроонкологии. Опухоли мозга, глиобластома, метастазы в ЦНС.
Организатор: SNO
Организатор: ESTRO
Организатор: EAU
Организатор: EBMT Educational Events & Meetings
Организатор: ESGO Meeting Calendar
Организатор: OncoSib — Ассоциация онкологических организаций Сибири и ДВ
Организатор: OncoSib — Ассоциация онкологических организаций Сибири и ДВ
Организатор: НМИЦ онкологии им. Н.Н. Петрова
Организатор: НМИЦ радиологии Минздрава России
Организатор: College of American Pathologists (CAP) Events
Организатор: ESMO Meeting Calendar
Организатор: ESTRO
Организатор: IASLC Conferences
Организатор: MASCC Supportive Care Events
Организатор: ESMO Meeting Calendar
Организатор: SIOP Community Calendar
Организатор: Onco-Academy
Организатор: Onco-Academy
Организатор: НМИЦ онкологии им. Н.Н. Петрова
Организатор: ESMO Meeting Calendar
Организатор: НМИЦ радиологии Минздрава России
Организатор: НМИЦ радиологии Минздрава России
Организатор: European School of Oncology (ESO)
Организатор: ESGO Meeting Calendar
Организатор: ESGO Meeting Calendar
Организатор: ESGO Meeting Calendar
Организатор: EAU
Организатор: Научный клуб онкологии, радиотерапии и реконструктивной хирургии им. Л.Л. Левшина и СНК ортодонтии и профилактики
Организатор: ФГБУ «НМИЦ гематологии» Минздрава России, Национальное гематологическое общество, Фонд борьбы с лейкемией
Организатор: Онкологический онлайн-марафон
